MDGL Q3 2025 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$287M+362.0% YoY

Gross Profit

$269M93.7% margin

Operating Income

-$114M-39.7% margin

Net Income

-$114M-39.8% margin

EPS (Diluted)

$-5.08

QoQ Revenue Growth

+35.0%

Cash Flow

Operating Cash Flow

$80M

Free Cash Flow

$79M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$737M

Stockholders' Equity

$626M

Cash & Equivalents

$296M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$287M	$62M	+362.0%
Gross Profit	$269M	$60M	+348.4%
Operating Income	-$114M	-$116M	+2.0%
Net Income	-$114M	-$107M	-6.8%

Revenue Segments

Reportable Segment

$287M100%